Correction to: Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability (AAPS PharmSciTech, (2018), 19, 2, (837-844), 10.1208/s12249-017-0891-1);Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability

AAPS PharmSciTech

Volumn 19, Issue 2, 2018, Pages 837-844

  Doty, Amber ^a   Schroeder, Jon ^a   Vang, Kou ^a   Sommerville, Mark ^a   Taylor, Mervin ^a   Flynn, Brad ^a   Lechuga Ballesteros, David ^a   Mack, Peter ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

chronic obstructive pulmonary disease (COPD); co suspension delivery technology; dose consistency; metered dose inhaler (MDI); respiratory drug delivery

Indexed keywords

FLUORINATED HYDROCARBON; FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE; PHOSPHOLIPID; PROPELLANT; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; GLYCOPYRRONIUM; MUSCARINIC RECEPTOR BLOCKING AGENT;

AEROSOL; ARTICLE; CRYSTAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; DRUG STORAGE; FLOW RATE; IN VITRO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; RELIABILITY; SHELF LIFE; SIMULATION; SUSPENSION; ADMINISTRATION AND DOSAGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOUBLE BLIND PROCEDURE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INVENTION; METABOLISM; METERED DOSE INHALER; PHARMACOKINETICS; PROCEDURES; REPRODUCIBILITY; STANDARDS;

ADMINISTRATION, INHALATION; AEROSOLS; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FORMOTEROL FUMARATE; GLYCOPYRROLATE; HUMANS; INVENTIONS; METERED DOSE INHALERS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SUSPENSIONS;

EID: 85030867389     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-017-0916-9     Document Type: Erratum

References (35)

1. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11(3):404–6.
2. Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J. 2009;18(4):243–9.
3. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–8.
4. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16(3):249–54.
5. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers—into the new millennium. Int J Pharm. 2000;201(1):89–107.
6. Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech. 2014;15(2):434–55.
7. Smyth HD. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev. 2003;55(7):807–28.
8. Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42):15015–23.
9. Rogueda P. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Expert Opin Drug Deliv. 2005;2(4):625–38.
10. Molimard M, Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2015;28(3):219–28.
11. Bosnic-Anticevich SZ, Sinha H, So S, Reddel HK. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. J Asthma. 2010;47(3):251–6.
12. Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med. 2006;100(9):1479–94.
13. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395–401.
14. Hatley RH, Parker J, Pritchard JN, von Hollen D. Variability in delivered dose from pressurized metered-dose inhaler formulations due to a delay between shake and fire. J Aerosol Med Pulm Drug Deliv. 2017;30(1):71–9.
15. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, et al. Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17(2):168–74.
16. AstraZeneca Pharmaceuticals LP. Bevespi Aerosphere Prescribing Information. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208294s000lbl.pdf Accessed 27 May 2017.
17. Lechuga-Ballesteros D, Vehring R, Dwivedi SK. A new co-suspension MDI platform: scientific foundations of mono, dual and triple combination products. RDD Eur. 2011;1:101–12.
18. Ivey JW, Vehring R. The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development. Comput Chem Eng. 2010;34(7):1036–40.
19. Cummings H, Schultz RD, Speck JH, Joshi V, Lechuga-Ballesteros D, Flynn B, et al. Performance advantages of Pearl co-suspension formulation technology for manufacturing of metered-dose inhalers. RDD Eur. 2011;2:387–90.
20. Nimmo CJ, Chen DN, Martinusen SM, Ustad TL, Ostrow DN. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann Pharmacother. 1993;27(7–8):922–7.
21. Hesselink AE, Penninx BW, Wijnhoven HA, Kriegsman DM, van Eijk JT. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scand J Prim Health Care. 2001;19(4):255–60.
22. Janssens W, VandenBrande P, Hardeman E, De Langhe E, Philps T, Troosters T, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83.
23. Chambers F, Ludzik A. In vitro drug delivery performance of a new budesonide/formoterol pressurized metered-dose inhaler. J Aerosol Med Pulm Drug Deliv. 2009;22(2):113–20.
24. Johal B, Howald M, Fischer M, Marshall J, Venthoye G. Fine particle profile of fluticasone propionate/formoterol fumarate versus other combination products: the DIFFUSE Study. Comb Prod Ther. 2013;3(1):39–51.
25. Hatley RH, von Hollen D, Sandell D, Slator L. In vitro characterization of the OptiChamber Diamond valved holding chamber. J Aerosol Med Pulm Drug Deliv. 2014;27(Suppl 1):S24–36.
26. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12(6):1346.
27. ®: a high-efficiency combination metered dose inhaler with consistent particle size distribution at alternative flow rates. Comb Prod Ther. 2014;4(1):1–5.
28. Newman SP. Principles of metered-dose inhaler design. Respir Care. 2005;50(9):1177–90.
29. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209–27.
30. Lechuga-Ballesteros D, Noga B, Vehring R, Cummings RH, Dwivedi SK. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3(13):1703–18.
31. Traini D, Young PM, Rogueda P, Price R. In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers. Pharm Res. 2007;24(1):125–35.
32. Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J Aerosol Med. 1996;9(2):215–26.
33. Everard ML, Devadason SG, Summers QA, Le Souef PN. Factors affecting total and “respirable” dose delivered by a salbutamol metered dose inhaler. Thorax. 1995;50(7):746–9.
34. Thorsson L, Edsbacker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J. 1998;12(6):1340–5.
35. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–64.